Literature DB >> 24940492

Cyclin D1 expression in Bowen's disease and cutaneous squamous cell carcinoma.

Yanyun Shen1, Jinhua Xu1, Jin Jin1, Hui Tang1, Jun Liang1.   

Abstract

Cyclin D1 is a member of the G1 cyclin family that regulates the transition through the G1 phase of the cell cycle and is involved in the neoplastic transformation of certain tumors. This study was designed to investigate the expression of cyclin D1 in Bowen's disease (BD) and cutaneous squamous cell carcinoma (SCC). Biopsies of 30 cases with BD and 24 cases with SCC confirmed by histopathology were obtained from the Department of Dermatology of Huashan Hospital, Shanghai, China. EnVision immunohistochemical technology with a semiquantitative immunohistochemical score was applied to detect the expression of cyclin D1. Of the 24 specimens with SCC, cyclin D1 was found to be positive in 17 (70.8%), whereas of the 30 specimens with BD, cyclin D1 was found to be positive in 13 (43.3%). The expression of cyclin D1 was significantly higher in the SCC compared to that in the BD group. We did not observe a significant association of cyclin D1 expression with different pathological grades of SCC. In conclusion, cyclin D1 plays a significant role as a diagnostic marker in skin tumors and its overexpression was not found to be correlated with the degree of differentiation of SCC.

Entities:  

Keywords:  Bowen’s disease; cutaneous squamous cell carcinoma; cyclin D1; immunohistochemistry

Year:  2014        PMID: 24940492      PMCID: PMC4051557          DOI: 10.3892/mco.2014.273

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  26 in total

1.  Cyclin D1 expression in oral squamous cell carcinoma and verrucous carcinoma: correlation with histological differentiation.

Authors:  Punnya V Angadi; Rekha Krishnapillai
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2007-01-02

2.  Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus.

Authors:  D S Bae; S B Cho; Y J Kim; J D Whang; S Y Song; C S Park; D S Kim; J H Lee
Journal:  Gynecol Oncol       Date:  2001-06       Impact factor: 5.482

Review 3.  Molecular and cellular biology of basal cell carcinoma.

Authors:  Tony Dicker; Gregory Siller; Nicholas Saunders
Journal:  Australas J Dermatol       Date:  2002-11       Impact factor: 2.875

4.  Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas: correlation of protein expression with lymph node metastases and advanced clinical stage.

Authors:  N S Fracchiolla; G Pruneri; L Pignataro; N Carboni; P Capaccio; A Boletini; R Buffa; A Neri
Journal:  Cancer       Date:  1997-03-15       Impact factor: 6.860

5.  p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus.

Authors:  Xue Ying Shi; Brahm Bhagwandeen; Anthony S-Y Leong
Journal:  Appl Immunohistochem Mol Morphol       Date:  2008-10

Review 6.  Cell cycle dysregulation in oral cancer.

Authors:  R Todd; P W Hinds; K Munger; A K Rustgi; O G Opitz; Y Suliman; D T Wong
Journal:  Crit Rev Oral Biol Med       Date:  2002

7.  Cyclin D1-a prognostic marker in oropharyngeal squamous cell carcinoma that is tightly associated with high-risk human papillomavirus status.

Authors:  Juliette B Scantlebury; Jingqin Luo; Wade L Thorstad; Samir K El-Mofty; James S Lewis
Journal:  Hum Pathol       Date:  2013-04-06       Impact factor: 3.466

8.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

Authors:  Frederik Holst; Phillip R Stahl; Christian Ruiz; Olaf Hellwinkel; Zeenath Jehan; Marc Wendland; Annette Lebeau; Luigi Terracciano; Khawla Al-Kuraya; Fritz Jänicke; Guido Sauter; Ronald Simon
Journal:  Nat Genet       Date:  2007-04-08       Impact factor: 38.330

9.  Cyclin d1 expression and its correlation with histopathological differentiation in oral squamous cell carcinoma.

Authors:  Swati Saawarn; Madhusudan Astekar; Nisheeth Saawarn; Nidhi Dhakar; Shitalkumar Gomateshwar Sagari
Journal:  ScientificWorldJournal       Date:  2012-05-02

10.  CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.

Authors:  Somaia Elsheikh; Andrew R Green; Mohammed A Aleskandarany; Matthew Grainge; Claire E Paish; Maryou B K Lambros; Jorge S Reis-Filho; Ian O Ellis
Journal:  Breast Cancer Res Treat       Date:  2007-07-26       Impact factor: 4.872

View more
  6 in total

1.  Expression of FOXC2, PinX1, Ki-67 and Cyclin D1 in cutaneous cell carcinoma.

Authors:  Haiying Zhao; Yunfeng Cao; Guoqiang Wang; Zengxiang Luo
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

2.  Identification of mTOR inhibitor-resistant genes in cutaneous squamous cell carcinoma.

Authors:  Seong-Lan Yu; Dong Chul Lee; Seung Woo Baek; Do Yeun Cho; Jong Gwon Choi; JaeKu Kang
Journal:  Cancer Manag Res       Date:  2018-11-27       Impact factor: 3.989

Review 3.  Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.

Authors:  Luca Fania; Dario Didona; Francesca Romana Di Pietro; Sofia Verkhovskaia; Roberto Morese; Giovanni Paolino; Michele Donati; Francesca Ricci; Valeria Coco; Francesco Ricci; Eleonora Candi; Damiano Abeni; Elena Dellambra
Journal:  Biomedicines       Date:  2021-02-09

Review 4.  Oh, the Mutations You'll Acquire! A Systematic Overview of Cutaneous Squamous Cell Carcinoma.

Authors:  Stephenie Droll; Xiaomin Bao
Journal:  Cell Physiol Biochem       Date:  2021-09-22

5.  Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas.

Authors:  Doris Helbig; Michaela Angelika Ihle; Katharina Pütz; Iliana Tantcheva-Poor; Cornelia Mauch; Reinhard Büttner; Alexander Quaas
Journal:  Oncotarget       Date:  2016-04-19

6.  Targeting PRPK and TOPK for skin cancer prevention and therapy.

Authors:  Eunmiri Roh; Mee-Hyun Lee; Tatyana A Zykova; Feng Zhu; Janos Nadas; Hong-Gyum Kim; Ki Beom Bae; Yan Li; Yong Yeon Cho; Clara Curiel-Lewandrowski; Janine Einspahr; Sally E Dickinson; Ann M Bode; Zigang Dong
Journal:  Oncogene       Date:  2018-06-14       Impact factor: 9.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.